KCT0000531招募中未知
Clinical trials to compare the pharmacokinetics profile of DWCZP tablet 100mg and Clozaril® tablet 100mg after a multi-dose oral administration in Schizophrenia patients.
Dong Hwa Pharm0 个研究点目标入组 28 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 60(Year)（—）
- 性别
- All
入选标准
- •Adult male or female within range of 20 to 60.
- •- Diagnosed as Schizophrenia (Note: Diagnosed with DSM-IV, ICD-10 as a standard Schizophrenia diagnostic tool).
- •- Administered clozapine for 3 months before signing agreement with same amount daily and who can administer clozapine 100mg twice (morning, evening) a day, total of 200mg during the study time.
- •- One who might be pregnant must get negative result for pregnancy test (urine or blood ß-hCG) before the randomization and during the study time, one must agree appropriate contraception. However, one who is using only hormone-contraceptive for birth control and has not been more that 1 year after Tubal liagtion or menopause are excluded.
- •- One who understood completed about this study after the explanation is given, decided to volunteer and gave written informed consent approved by IRB to participate in study in compliance with the requirement of the entire protocol.
排除标准
- •- One who has record of hypersensitive reaction with Clozapine or other antipsychotic drug.
- •- WBC count less than 4,000/ml or Absolute Neutrophil count less than 2,000/ml.
- •- Administering hypertension drug or has orthostatic hypotension.
- •- One who has clinical problem with kidney or liver and include following criteria: CCr < 50mL/min; BUN > 30 mg/dl; ALT ?? AST > 3 x ULN; Total bilirubin > 2 x ULN; ALP > 2 x ULN.
- •- Diagnosed to have other psychiatric or neurological problems other than Schizophrenia (e.g., Organic mental disorder, severe tardive dyskinesia, idiopathic Parkinson's disease, etc).
- •- Record of Granulocytopenia or Myeloproliferative disorder in the past.
- •- Record of stomach-related problems(active Crohn's disease, vital infectious intestine disease, ulcer, acute or chronic pancreatitis etc) or surgery which can affect absorption of study drug. However, simple appendectomy or herniotomy are exceptions.
- •- Chronic Hepatitis B carrier, proof of Hepatitis C carrier or Hepatitis C antibody.
- •- Immunodeficiency diseases such as HIV positive, AIDS, had bone marrow transplantation or has blood ammonia.
- •- Record of seizure in 1 year before sigining informed consent form or had administered anti-seizure drug before(e.g., Epilepsy, Convulsions, Myasthenia gravis, etc).
- •- One who consitantly drinks(> 21Units/week, 1Unit = 10g of pure alcohol) or cannot stop drinking alcohol during hospitalization period.
- •- Smoking past 3 months before signing informed consent form or cannot stop smoking during hospitalization period.
- •- One who cannot attend routine blood tests.
- •- Bone marrow malfunction.
- •- Mental illness, durg addicted or in coma.
- •- One who has any kind of circulation imperfection and patient with depressed central nervous system.
- •- Major kidney and heart problem(e.g. myocarditis).
- •- Incuarable epilepsy.
- •- Paralytic intestinal obstruction.
- •- Generic problems such as Lactose intolerance, Galactose intolerance, Lapp lactose deficiency, Glucose-Galactose absortion deficiency, etc.
- •- Administered barbital-related drugs and drug metabolizing enzyme inducer and inhibitor in 1 month before starting the study.
- •- One who had drugs that can affect on result of the study for past 10 days before the study start.
- •- One who had whole blood donation in 2 months or blood component donation or transfusion in 1 month before signing the informed consent form.
- •- Attended clinical tests or bioequivalence tests in 2 months before signing informed consent form.
- •- Currently pregnant or breast-feeding or has possibility of pregnancy because one is not using medically approved contraception(Note: condoms, oral contraceptive, intrauterine device, abstinence etc).
- •- One who is clinically significant by observations considered as unsuitable based on medical judgement by investigators.
研究者
相似试验
进行中（未招募）
不适用
A trial to compare the pharmacokinetics and pharmacodynamics of insulin lispro administered s.c. into lipohypertrophic or normal abdominal adipose tissue in subjects with diabetes mellitus type 1MedDRA version: 17.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes mellitusEUCTR2014-003144-12-DEProfil Institut für Stoffwechselforschung GmbH
进行中（未招募）
1 期
A research study of how fast-acting insulin aspart works in the body of children, young people and grown-ups with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 20.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2017-002014-31-DEovo Nordisk A/S43
招募中
不适用
Clinical Trials to Compare the Pharmacokinetic Profiles of Sarpogrelate hydrochloride 300mg SR Tablet and ANPLAG® IR After Multiple Oral Administration to Healthy Male SubjectsKCT0000156Kunwha Pharmaceutical18
招募中
不适用
Clinical Trials to Compare the Pharmacokinetic Profiles of Sarpogrelate hydrochloride 300mg SR Tablet and ANPLAG® IR After Oral Administration to Healthy Male SubjectsKCT0000202Kunwha Pharmaceutical18
尚未招募
不适用
Pharmacokinetic drug interaction between celecoxib and rebamipideKCT0000381Hanlim Pharmaceutical30